Cantor Fitzgerald Weighs in on AxoGen FY2024 Earnings

AxoGen, Inc. (NASDAQ:AXGN) – Equities research analysts at Cantor Fitzgerald reduced their FY2024 earnings per share estimates for AxoGen in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn now forecasts that the medical equipment provider will earn ($0.58) per share for the year, down from their prior estimate of ($0.28). The consensus estimate for AxoGen’s current full-year earnings is ($0.30) per share. Cantor Fitzgerald also issued estimates for AxoGen’s FY2025 earnings at $0.19 EPS.

Separately, StockNews.com upgraded AxoGen from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th.

AxoGen Trading Down 1.0 %

NASDAQ AXGN opened at $18.70 on Thursday. AxoGen has a 12 month low of $5.55 and a 12 month high of $19.06. The stock has a 50-day simple moving average of $15.53 and a 200 day simple moving average of $13.34. The company has a market capitalization of $822.99 million, a PE ratio of -58.44 and a beta of 1.01. The company has a current ratio of 3.74, a quick ratio of 2.47 and a debt-to-equity ratio of 0.67.

Institutional Investors Weigh In On AxoGen

Several large investors have recently modified their holdings of AXGN. R Squared Ltd acquired a new position in shares of AxoGen during the fourth quarter worth about $30,000. SG Americas Securities LLC boosted its position in shares of AxoGen by 34.4% during the fourth quarter. SG Americas Securities LLC now owns 21,763 shares of the medical equipment provider’s stock worth $359,000 after buying an additional 5,576 shares during the period. JPMorgan Chase & Co. boosted its position in shares of AxoGen by 2,912.3% during the third quarter. JPMorgan Chase & Co. now owns 549,000 shares of the medical equipment provider’s stock worth $7,697,000 after buying an additional 530,775 shares during the period. Principal Financial Group Inc. acquired a new position in shares of AxoGen during the third quarter worth about $207,000. Finally, Franklin Resources Inc. boosted its position in shares of AxoGen by 9.8% during the third quarter. Franklin Resources Inc. now owns 76,048 shares of the medical equipment provider’s stock worth $1,084,000 after buying an additional 6,767 shares during the period. 80.29% of the stock is currently owned by institutional investors.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.